Both support natural growth hormone production, but they work in slightly different ways
Realistic expectations matter here
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
These include: Obtaining a prior authorization (special approval from your insurance company) Going through step therapy, which involves trying a lower-cost medication first Meeting with a dietitian or joining a weight-loss program Nearly 74% of U.S
According to Reuters , Saad said Canada is very important for us since many Latin American and Middle Eastern regulators use it as a reference for strict oversight
doi: 10.1038/ni1276 135 Montero-MelendezTBoesenTJonassenTEN